"Both the 80 mg and the 100 mg dose of Resmetirom
Post# of 149108
"Will compare Leronlimab with a GLP-1 agonist (Semaglutide) in addition to Confirming the Comparison with Resmetirom...aka (Rezdiffra)...FDA approved.
In September, Cytodyn launched (two) follow-up studies which will become Available in January 2025.
Last letter to shareholders Dec 17th/2024...I expect PR before end of Jan.
Madrigal closed @ $319.69 for 1/3/25...with the daily bump of $5.91.
Cytodyn closed @ $0.1189 " ".
I would take their daily bump as a SP...to start.